191 related articles for article (PubMed ID: 20403488)
1. Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure.
Desai H; Aronow WS; Ahn C; Gandhi K; Hussain S; Lai HM; Sharma M; Frishman WH; Cohen M; Sorbera C
Am J Cardiol; 2010 May; 105(9):1336-8. PubMed ID: 20403488
[TBL] [Abstract][Full Text] [Related]
2. Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter-defibrillator therapy.
Desai H; Aronow WS; Ahn C; Tsai FS; Lai HM; Gandhi K; Amin H; Frishman WH; Kalapatapu K; Cohen M; Sorbera C
J Cardiovasc Pharmacol Ther; 2010 Mar; 15(1):37-40. PubMed ID: 19966176
[TBL] [Abstract][Full Text] [Related]
3. Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter-defibrillator therapy.
Desai H; Aronow WS; Tsai FS; Ahn C; Lai HM; Amin H; Gandhi K; Frishman WH; Cohen M; Sorbera C
J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):176-9. PubMed ID: 19617418
[TBL] [Abstract][Full Text] [Related]
4. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.
Daubert JP; Zareba W; Cannom DS; McNitt S; Rosero SZ; Wang P; Schuger C; Steinberg JS; Higgins SL; Wilber DJ; Klein H; Andrews ML; Hall WJ; Moss AJ;
J Am Coll Cardiol; 2008 Apr; 51(14):1357-65. PubMed ID: 18387436
[TBL] [Abstract][Full Text] [Related]
5. Relation of advanced heart failure symptoms to risk of inappropriate defibrillator shocks.
Hreybe H; Ezzeddine R; Barrington W; Bazaz R; Jain S; Ngwu O; Saba S
Am J Cardiol; 2006 Feb; 97(4):544-6. PubMed ID: 16461053
[TBL] [Abstract][Full Text] [Related]
6. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
[TBL] [Abstract][Full Text] [Related]
7. Mortality rates and clinical predictors of reduced survival after cardioverter defibrillator implantation.
Thibodeau JB; Pillarisetti J; Khumri TM; Jones PG; Main ML
Am J Cardiol; 2008 Mar; 101(6):861-4. PubMed ID: 18328854
[TBL] [Abstract][Full Text] [Related]
8. Prognostic importance of atrial fibrillation in implantable cardioverter-defibrillator patients.
Borleffs CJ; van Rees JB; van Welsenes GH; van der Velde ET; van Erven L; Bax JJ; Schalij MJ
J Am Coll Cardiol; 2010 Mar; 55(9):879-85. PubMed ID: 20185038
[TBL] [Abstract][Full Text] [Related]
9. Ventricular proarrhythmic effects of atrial fibrillation are modulated by depolarization and repolarization anomalies in patients with left ventricular dysfunction.
Lemola K; Khan R; Nattel S; Talajic M; Roy D; Guerra PG; Lemola S; Dubuc M; Thibault B; Macle L; Khairy P
Pacing Clin Electrophysiol; 2009 Jan; 32(1):99-105. PubMed ID: 19140919
[TBL] [Abstract][Full Text] [Related]
10. Implantable cardioverter-defibrillator shocks in patients with a left ventricular assist device.
Ambardekar AV; Allen LA; Lindenfeld J; Lowery CM; Cannon AP; Cleveland JC; Brieke A; Sauer WH
J Heart Lung Transplant; 2010 Jul; 29(7):771-6. PubMed ID: 20347337
[TBL] [Abstract][Full Text] [Related]
11. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
[TBL] [Abstract][Full Text] [Related]
12. Persistent atrial fibrillation is associated with appropriate shocks and heart failure in patients with left ventricular dysfunction treated with an implantable cardioverter defibrillator.
Rienstra M; Smit MD; Nieuwland W; Tan ES; Wiesfeld AC; Anthonio RL; Van den Berg MP; Van Veldhuisen DJ; Van Gelder IC
Am Heart J; 2007 Jan; 153(1):120-6. PubMed ID: 17174649
[TBL] [Abstract][Full Text] [Related]
13. Atrial fibrillation in cardiac resynchronization therapy with a defibrillator: a risk factor for mortality, appropriate and inappropriate shocks.
van Boven N; Theuns D; Bogaard K; Ruiter J; Kimman G; Berman L; VAN DER Ploeg T; Kardys I; Umans V
J Cardiovasc Electrophysiol; 2013 Oct; 24(10):1116-22. PubMed ID: 23889733
[TBL] [Abstract][Full Text] [Related]
14. Comparison between atrial fibrillation-triggered implantable cardioverter-defibrillator (ICD) shocks and inappropriate shocks caused by lead failure: different impact on prognosis in clinical practice.
Kleemann T; Hochadel M; Strauss M; Skarlos A; Seidl K; Zahn R
J Cardiovasc Electrophysiol; 2012 Jul; 23(7):735-40. PubMed ID: 22313314
[TBL] [Abstract][Full Text] [Related]
15. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
[TBL] [Abstract][Full Text] [Related]
16. Prediction of appropriate defibrillator therapy in heart failure patients treated with cardiac resynchronization therapy.
Soliman OI; Theuns DA; van Dalen BM; Vletter WB; Nemes A; Jordaens LJ; Balk AH; Ten Cate FJ; Geleijnse ML
Am J Cardiol; 2010 Jan; 105(1):105-11. PubMed ID: 20102900
[TBL] [Abstract][Full Text] [Related]
17. Right ventricular pacing is associated with impaired overall survival, but not with an increased incidence of ventricular tachyarrhythmias in routine cardioverter/defibrillator recipients with reservedly programmed pacing.
Stockburger M; Celebi O; Krebs A; Knaus T; Nitardy A; Habedank D; Dietz R
Europace; 2009 Jul; 11(7):924-30. PubMed ID: 19447808
[TBL] [Abstract][Full Text] [Related]
18. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics.
Alexander ME; Cecchin F; Walsh EP; Triedman JK; Bevilacqua LM; Berul CI
J Cardiovasc Electrophysiol; 2004 Jan; 15(1):72-6. PubMed ID: 15028076
[TBL] [Abstract][Full Text] [Related]
19. Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT.
Sood N; Ruwald AC; Solomon S; Daubert JP; McNitt S; Polonsky B; Jons C; Clyne CA; Zareba W; Moss AJ
Eur Heart J; 2014 Jan; 35(2):106-15. PubMed ID: 24179073
[TBL] [Abstract][Full Text] [Related]
20. Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).
Ruwald AC; Schuger C; Moss AJ; Kutyifa V; Olshansky B; Greenberg H; Cannom DS; Estes NA; Ruwald MH; Huang DT; Klein H; McNitt S; Beck CA; Goldstein R; Brown MW; Kautzner J; Shoda M; Wilber D; Zareba W; Daubert JP
Circ Arrhythm Electrophysiol; 2014 Oct; 7(5):785-92. PubMed ID: 25136077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
